SRR35579823
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.610
- INTERFERON_GAMMA_RESPONSE+0.600
- IL6_JAK_STAT3_SIGNALING+0.540
- ALLOGRAFT_REJECTION+0.530
- INFLAMMATORY_RESPONSE+0.510
- TNFA_SIGNALING_VIA_NFKB+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- COMPLEMENT+0.410
- KRAS_SIGNALING_UP+0.380
- IL2_STAT5_SIGNALING+0.370
Top 10 suppressed
- MYC_TARGETS_V2-0.310
- OXIDATIVE_PHOSPHORYLATION-0.310
- DNA_REPAIR-0.270
- ADIPOGENESIS-0.240
- BILE_ACID_METABOLISM-0.210
- FATTY_ACID_METABOLISM-0.160
- PEROXISOME-0.160
- ESTROGEN_RESPONSE_EARLY-0.150
- MYC_TARGETS_V1-0.100
- KRAS_SIGNALING_DN-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.922 |
| 2 | TCGA-44-2668-01A-01R-0946-07 | — | cohortA1 | 0.910 |
| 3 | SJEPD030232_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.887 |
| 4 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.886 |
| 5 | TCGA-CN-4734-01A-01R-1436-07 | — | — | 0.884 |
| 6 | SRR10900560 | — | — | 0.878 |
| 7 | SRR1516052 | — | — | 0.874 |
| 8 | TCGA-BH-A1F0-01A-11R-A137-07 | — | D | 0.872 |
| 9 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.872 |
| 10 | SRR934862 | — | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.540 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.260 | Inavolisib | — uncovered |